PhorMed is at the forefront of biotechnology innovation with our flagship pharmaceutical agent, designated as RP-323. We are working to utilize gene therapy to treat diseases, allowing the body to heal and giving new hope to patients suffering from diseases like AML, Hodgkin’s Lymphoma, ARDS, Parkinson’s disease, and viruses.
| Website | https://wefunder.com/phormed |
| Revenue | $18.4 million |
| Employees | 5 (3 on RocketReach) |
| Address | 2121 Avenue of the Stars Ste. 800, Los Angeles, California 90067, US |
| Technologies |
JavaScript
,
HTML
,
PHP
+10 more
(view full list)
|
| Industry | Biotechnology Research |
| Keywords | Precision Medicine, Gene Therapy, Novel Therapeutics, Biotechnology, Pharmaceutical Agent, Disease Treatment, Clinical Trials, Drug Development, Biotech Innovation, Medical Research, Healthcare, Therapeutics, Genetic Engineering, Pharmaceutical, Biomedicine, Life Sciences, Molecular Biology, Cell Therapy, Regenerative Medicine |
| Competitors | Roche, Amgen, Thermo Fisher Scientific, AbbVie, Johnson & Johnson, BD, GE HealthCare, Fresenius Kabi, Siemens Healthineers, Mylan Belgium +43 more (view full list) |
Looking for a particular PhorMed employee's phone or email?
The PhorMed annual revenue was $18.4 million in 2026.
McCoy Moretz is the CEO of PhorMed.
3 people are employed at PhorMed.
PhorMed is based in Los Angeles, California.